ACB HealthcareBeta data

Aurora Cannabis Inc.

$5.16+22.27%

Price as of close on Nov 3, 2026 · Financials updated Oct 31, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Canada
Market cap: 326.7M USD
Enterprise value: 271.3M USD
Full-time employees: 1,028

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.42 vs a peer median of 0.63)bigger price swings (beta 1.42 vs peers 0.63)
About average: risk (debt, liquidity and share-price swings)risk
Not enough data: growth

Would rank #825 of 1,157 fully scored healthcare companies (bottom 29%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on operating cash profit (EBITDA).Cheaper than 50% of peers on free cash flow, but only 0% on operating cash profit.
Relative to its free cash flow, Aurora Cannabis looks cheaper than 50% of peers; relative to its operating cash profit (EBITDA), cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its free cash flow, Aurora Cannabis looks cheaper than 50% of peers; relative to its operating cash profit, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
More volatile share price. Beta 1.42: tends to move more than the market.
Aurora Cannabis's shares have swung more with the market than most peers' (beta 1.42, above the market's 1.0).

StockQuotient Score

40/ 100▲ 1 since Oct 27 close

Oct 5 40 → Nov 4 40

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

30/100

Weak

2/3 inputs reported · Partial data

Why

Weaker than most peers on:

▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0148 · MAD: 0.0148

EBITDA yield-7.9%

Yahoo Finance · trailing 12 months · CAD→USD convertedNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-11.2%

Yahoo Finance · trailing 12 months · CAD→USD converted · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield112.1%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

30/100

Weak

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Operating margin
▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-14.6%

Yahoo Finance · fiscal year to Mar 2026Reported value33% base weight · Z-score -1.78Sector median: 0.0706 · MAD: 0.1217

Return on assets-3.7%

Yahoo Finance · trailing 12 monthsReported value33% base weight · Z-score -1.00Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-10.8%

Yahoo Finance · trailing 12 monthsReported value33% base weight · Z-score -1.54Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin44.2%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-9.4%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Why it changed since the Oct 27, 2026 close: Safety percentile 58 → 59

Company's reported figures updated+1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Mixed versus peers:

▲ Debt / equity
▲ Current ratio
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.42

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -2.36Sector median: 0.6250 · MAD: 0.3380

Current ratio5.36×

Yahoo FinanceReported value33% base weight · Z-score 2.00Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.04×

Yahoo FinanceReported value33% base weight · Z-score 0.88Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Aurora Cannabis

Is Aurora Cannabis getting weaker?: Filing-by-filing changes are tracked only for companies that file with the US SEC. Its overall score is 40/100, up 1 since Oct 28, 2026.
How is Aurora Cannabis valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 30/100 against 1,393 healthcare peers. EBITDA yield -7.9% vs a peer median of 4.0% (weaker than 100% of peers).EBITDA yield -7.9% vs peers 4.0% (weaker than 100% of peers).
Is Aurora Cannabis growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Aurora Cannabis?: Less profitable than most of its peers. Profitability scores 30/100 against 1,393 healthcare peers. Operating margin -14.6% vs a peer median of 7.1% (weaker than 76% of peers).Operating margin -14.6% vs peers 7.1% (weaker than 76% of peers).
How risky is Aurora Cannabis?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.04× vs a peer median of 0.22× (stronger than 78% of peers).Debt / equity 0.04× vs peers 0.22× (stronger than 78% of peers). Beta 1.42 vs a peer median of 0.63 (weaker than 86% of peers).Beta 1.42 vs peers 0.63 (weaker than 86% of peers). A relative measure, not a bankruptcy probability.

Financials

Detailed annual statements come from structured SEC filing data, which most US companies and some foreign filers provide. They aren’t available for this company yet.

ACB price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.42 vs a peer median of 0.63)bigger price swings (beta 1.42 vs peers 0.63)

About average: risk (debt, liquidity and share-price swings)risk

Not enough data: growth

Would rank #825 of 1,157 fully scored healthcare companies (bottom 29%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on operating cash profit (EBITDA).Cheaper than 50% of peers on free cash flow, but only 0% on operating cash profit.

Relative to its free cash flow, Aurora Cannabis looks cheaper than 50% of peers; relative to its operating cash profit (EBITDA), cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its free cash flow, Aurora Cannabis looks cheaper than 50% of peers; relative to its operating cash profit, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

More volatile share price. Beta 1.42: tends to move more than the market.

Aurora Cannabis's shares have swung more with the market than most peers' (beta 1.42, above the market's 1.0).

Questions investors ask about Aurora Cannabis

Is Aurora Cannabis getting weaker?

Filing-by-filing changes are tracked only for companies that file with the US SEC. Its overall score is 40/100, up 1 since Oct 28, 2026.

How is Aurora Cannabis valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 30/100 against 1,393 healthcare peers. EBITDA yield -7.9% vs a peer median of 4.0% (weaker than 100% of peers).EBITDA yield -7.9% vs peers 4.0% (weaker than 100% of peers).

Is Aurora Cannabis growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Aurora Cannabis?

Less profitable than most of its peers. Profitability scores 30/100 against 1,393 healthcare peers. Operating margin -14.6% vs a peer median of 7.1% (weaker than 76% of peers).Operating margin -14.6% vs peers 7.1% (weaker than 76% of peers).

How risky is Aurora Cannabis?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.04× vs a peer median of 0.22× (stronger than 78% of peers).Debt / equity 0.04× vs peers 0.22× (stronger than 78% of peers). Beta 1.42 vs a peer median of 0.63 (weaker than 86% of peers).Beta 1.42 vs peers 0.63 (weaker than 86% of peers). A relative measure, not a bankruptcy probability.